Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pharmacy Union Concerns Unfounded
Concerns raised by the Pharmacists" Division of the Association of Professional

University Of Central Lancashire To Deliver Nurtured Heart Workshop, UK
Residential childcare and fostering agency, Perpetual Care, and the University of Central Lancashire"s School of Nursing & Caring Sciences are jointly developing an introductory workshop on the ground-breaking Nurtured Heart Approach, which seeks to improve social and educational outcomes for many children and young people. Experts from UCLan and Perpetual are currently designing an awareness workshop, which will provide an overview of the approach, examine existing US research findings and explore its potential role in UK residential childcare and fostering, particularly in the light of revised NICE guidelines relating to children with ADHD. The first session is scheduled at UCLan"s Preston campus in late June this year and should be of interest to registered social workers, local authority placement officers and other social care and health professionals concerned with the well-being of challenging young people.
News of the day
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has initiated a Phase 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira"s lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol, who are not well served by current therapy. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism.
Medical Devices

PPD Confirms Takeda Receives FDA Complete Response For Alogliptin

PPD, Inc. (NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin. PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin. PPD announced on March 6, 2009, that the FDA had informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA guidance. PPD


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009